Lymphoma

Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia,…

Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20…

Real-world data gained through scientific studies is essential in the advancement of treatments for all hematological malignancies. Historically, pharmaceutical companies…

Over the past two decades the treatment landscape for non-Hodgkin lymphoma (NHL) has rapidly evolved, with the development of Bruton’s…

Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such…

Immunotherapies are showing increasingly promising results for the treatment of patients with non-Hodgkin lymphoma (NHL) and, in particular, bispecific antibodies…

At present, four types of chimeric antigen receptor T-cell (CAR-T) therapy are FDA approved for specific types of lymphoma: for…

In this roundtable discussion, chaired by Gilles Salles, MD, PhD, Memorial Sloan Kettering, New York, NY; Nirav N. Shah, MD,…

Recent progress in the field of immunotherapy presents an exciting alternative to standard chemotherapy treatments for patients with non-Hodgkin lymphoma….

Over the last years, the chronic lymphocytic leukemia (CLL) field has seen significant growth in new drugs and new treatment…

The management of post-transplantation relapse and immune attack is an ongoing battle in patients undergoing bone marrow transplants. The efficacy…

The treatment of aggressive lymphomas such as diffuse large B-cell has seen dramatic changes, and with the advent of bispecific…